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Introduction
Patients with genitourinary (GU) malignancies 
are at risk for deterioration of bone throughout 
the disease continuum as a result of treatment, 
underlying disease, or both [Coleman, 2001; 
Saad et al. 2006]. Androgen-deprivation therapy 
for prostate cancer is associated with decreased 
bone mineral density, increased risk for osteopo-
rosis, and in one large meta-analysis, a 1.17-fold 
relative increase in the risk of skeletal fractures 
[Mittan et al. 2002; Serpa Neto et al. 2010]. 
Moreover, a significant proportion of patients 
with GU malignancies may develop metastatic 
skeletal involvement, further exacerbating loss of 
structural bone integrity [Coleman, 2001; Zekri 
et al. 2001; Woodward et al. 2011]. Bone metas-
tases are associated with a vicious cycle of bone 
destruction and tumor growth. As a result, 
patients with bone metastases typically experi-
ence severe bone pain and are at high risk of 
developing potentially debilitating skeletal-
related events (SREs) including pathological 
fractures or spinal cord compression that may 
require surgical or radiotherapy intervention 
[Coleman, 1997; Saad and Lipton, 2005]. 
Inevitably, SREs reduce a patient’s quality of life 
and functional independence, which are of par-
ticular relevance in patients who have a long life 
expectancy [Saad, 2008].
Antiresorptive therapies have demonstrated 
favorable efficacy in reducing bone pain and 
delaying the onset and reducing the risk of SREs 
[Saad et al. 2002, 2004; Lipton et al. 2003; Rosen 
et al. 2004; Bouganim et al. 2011; Fizazi et al. 
2011; Henry et al. 2011]. There are two main 
classes of antiresorptive compounds currently 
approved for prevention of SREs in patients with 
GU malignancies: bisphosphonates (BPs) and the 
more recently developed monoclonal antibody 
against the receptor activator of nuclear factor κB 
ligand (RANKL), denosumab (Dmab). There are 
important differences in the antiresorptive mech-
anisms of action and pharmacokinetics of BPs 
and Dmab that may result in differences in effi-
cacy and safety, particularly in oncology settings. 
This review focuses on fundamental differences 
between the two antiresorptive therapies and the 
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potential implications for use of these agents in 
the context of GU malignancies.
Mechanism of action of antiresorptive 
therapies in bone
Bisphosphonates are synthetic analogues of 
pyrophosphate that are resistant to enzymatic 
degradation through the substitution of the cen-
tral oxygen atom by a carbon atom [Yuasa et al. 
2007; Green and Clezardin, 2010]. Variation in 
the substituent groups bound to the central car-
bon account for differences in therapeutic activi-
ties of the BPs. There are two broad classifications 
of BPs: non-nitrogen-containing BPs and the 
most recent generation, nitrogen-containing BPs 
(NBPs), which have greater antiresorptive activ-
ity. Non–nitrogen-containing BPs are internalized 
and metabolized by osteoclasts to nonhydrolyz-
able adenosine triphosphate (ATP) analogues 
that inhibit osteoclast activity and lead to apop-
tosis [Yuasa et al. 2007]. In contrast, the NBPs 
inhibit farnesyl pyrophosphate synthase in the 
mevalonate pathway, thereby inhibiting the post-
translational prenylation and function of small 
guanosine 5′-triphosphatase (GTPase) proteins. 
Small GTPase proteins modulate signaling path-
ways that are essential for osteoclast function 
and survival [Green and Clezardin, 2010].
Denosumab inhibits osteoclast-mediated bone 
destruction by binding and neutralizing RANKL 
[Castellano et al. 2011]. Soluble and membrane-
bound RANKL, synthesized by various cell types 
including osteoblasts and activated T cells, plays 
a key role in normal bone remodeling by binding 
and activating the receptor activator of nuclear 
factor κB (RANK) receptor on the surface of 
osteoclasts. Activation of RANK modulates 
several signal transduction pathways, including 
protein kinase pathways and activation of the 
transcription factor nuclear factor κB that leads 
to stimulation of osteoclast formation, function, 
and survival and, as a result, increased bone 
resorption. Inhibition of RANKL by high-affin-
ity binding to Dmab prevents activation of 
RANK, thereby reducing bone resorption and 
increasing bone volume, density, and strength 
[Castellano et al. 2011].
Pharmacokinetics of antiresorptive therapies
Following intravenous administration, BPs are 
rapidly cleared from the systemic circulation 
by deposition in bone and renal excretion of 
unmetabolized drug within a few hours [Chen 
et al. 2002; Kimmel, 2007]. Bisphosphonates 
are retained in the bone via binding to areas of 
exposed hydroxyapatite crystals where they act 
to reduce bone resorption by osteoclasts. During 
bone remodeling, low levels of BP are released 
from bone, accounting for the longer terminal 
phase of elimination. Pharmacokinetics of the 
NBP zoledronic acid (ZOL) measured in patients 
with bone metastases demonstrate multiphasic 
plasma disposition with plasma half lives of 0.2 
and 1.4 h initially, followed by longer half lives 
of 39 and 4526 h for subsequent elimination 
phases of very low concentrations between day 2 
and day 28 post dose [Chen et al. 2002]. This 
study confirmed that the antiresorptive effects 
of ZOL persisted over 28 days, thus supporting 
monthly infusions of ZOL. Furthermore, a study 
evaluating adjuvant endocrine therapy in com-
bination with ZOL in women with early-stage 
breast cancer demonstrated that ZOL improved 
bone mineral density (BMD) for 2 years after 
discontinuation of ZOL therapy, suggesting a 
prolonged duration of effect [Gnant et al. 2008].
Denosumab is administered subcutaneously every 
4 weeks in patients with bone metastases; how-
ever, unlike BPs, Dmab is distributed systemically 
and follows nonlinear, dose-dependent pharma-
cokinetics with detectable serum levels as early as 
1 h post dose and maximum serum concentra-
tions within 1–3 weeks. Following a single 3 mg/kg 
injection, the elimination half life for Dmab 
ranged from 33.3 to 46.3 days in patients with 
multiple myeloma and breast cancer, respectively 
[Body et al. 2006]. These properties have clinical 
implications for specificity of action and duration 
of benefit. Because Dmab is not retained at its 
site of action in the bone, the antiresorptive effect 
of this agent is quickly reversed after the drug is 
cleared [Miller et al. 2008].
Incidence of skeletal-related events and 
clinical efficacy of antiresorptive agents
The clinical efficacy of antiresorptive agents is 
based on their ability to inhibit osteoclast-mediated 
bone degradation and thus prevent or delay devel-
opment of SREs (Table 1) [Saad et al. 2002, 
2004; Dearnaley et al. 2003, 2009; Ernst et al. 
2003; Lipton et al. 2003; Small et al. 2003; Saad 
and Lipton, 2005; Mason et al. 2007; Fizazi et al. 
2009, 2011; Zaghloul et al. 2010; Henry et al. 
2011]. Placebo-controlled trials of antiresorptive 
therapy in patients with GU malignancies and 
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Table 1. Efficacy of antiresorptive therapy for skeletal-related event prevention in patients with genitourinary cancers.
Study N Study population Arms Outcome
Saad et al. 
[2002]
Saad et al. 
[2004]     
643 CRPC 
(asymptomatic 
or minimally 
symptomatic)
ZOL 4 mg every 3 weeks 
versus PBO
for up to 24 months
At 15-month follow up (N = 643):
ZOL SREs (33.2% versus 44.2%, 
p = 0.021)
No difference in time to disease 
progression
Trend toward OS with ZOL
At 24-month follow up (n = 122):
ZOL SREs (38% versus 49%,  
p = 0.028)
ZOL time to first SRE (488 
versus 321 days, p = 0.009)
Lipton et al. 
[2003]
74 RCC with bone 
metastases
ZOL 4 mg versus PBO 
every 3 weeks for 9 
months
ZOL SREs 50% (37% versus 
74%, p = 0.015)
ZOL SMR (2.68 versus 3.38,  
p = 0.014)
 ZOL SRE risk by 61% (HR = 
0.394, p = 0.008)
Saad and Lipton 
[2005]
46 21 months ZOL SREs (41% versus 79%,  
p = 0.011)
Zaghloul et al. 
[2010]
 
 
40 Bladder cancer with 
bone metastases
Palliative radiation to 
affect bone followed 
by ZOL 4 mg or PBO 
monthly for 6 months
ZOL SREs (60% versus 90%;  
p = 0.010)
ZOL SMR (0.95 versus 2.05,  
p = 0.001)
ZOL 1-year survival (36.3% 
versus 0%, p = 0.004)
Small et al. 
[2003]
350 CRPC with 
symptomatic bone 
metastases
PAM 90 mg versus PBO 
every 3 weeks for 27 
weeks
No significant difference in SREs 
or palliation of bone pain
Ernst et al. 
[2003]
209 CRPC with 
symptomatic bone 
metastases
Mitoxantrone and 
prednisone ± CLO 1500 
mg every 3 weeks until 
progression
No significant difference in 
palliative response (pain intensity 
and analgesic use), PFS, or OS
Mason et al. 
[2007]
508 PC with no evidence 
of bone metastases 
(T2–T4)
Oral CLO 2080 mg/day 
versus PBO for up to 5 
years
No difference in symptomatic 
bone metastases or death  
from PC
Dearnaley et al. 
[2003, 2009]
311 Hormone-sensitive 
PC with bone 
metastases
Oral CLO 2080 mg/day 
or PBO for up to 3 yr
Trend toward OS with CLO (HR 
= 0.80, P = .082) at 5 yr
CLO OS (HR = 0.77; P = .032) 
with median follow-up of 11.5 yr 
Fizazi et al. 
[2009]
 
111
(Dmab  
n = 74; BP  
n = 37)
Solid tumors 
including PC with 
bone metastases 
and elevated 
NTX despite BP 
treatment for ≥ 8 
weeks
Dmab 180 mg 
subcutaneously every 
4 weeks or every 12 
weeks; ZOL or PAM 
every 4 weeks
Dmab NTX (71% versus 29%;  
p < 0.001)
First on-study SREs were lower 
with Dmab but not significantly 
different
Henry et al. 
[2011] 
1776 Solid tumors or 
MM (excluding BC 
and PC) with bone 
lesions
Subcutaneous Dmab 
120 mg plus intravenous 
placebo versus 
intravenous ZOL 4 mg 
plus subcutaneous PBO 
both arms every 4 weeks
Dmab was noninferior to ZOL in 
delaying first on-study SRE (HR = 
0.84; p = 0.0007)
OS and disease progression were 
similar between groups
(Continued)
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bone metastases show that without treatment, 
44–90% of patients will experience at least 1 SRE 
[Saad et al. 2002, 2004; Lipton et al. 2003; Saad 
and Lipton, 2005; Zaghloul et al. 2010; Woodward 
et al. 2011]. In the absence of bone-targeted ther-
apy, approximately half of patients with bone 
metastases from castration-resistant prostate can-
cer (CRPC) experienced an SRE [Saad et al. 
2004] and 79% of patients with bone metastases 
from renal cell carcinoma (RCC) experienced an 
SRE [Saad and Lipton,. 2005]. A small, prospec-
tive, placebo-controlled trial in patients with bone 
metastases from bladder cancer reported that 
90% of patients in the placebo group developed 
an SRE [Zaghloul et al. 2010]. The skeletal 
morbidity rate (mean SREs per patient years) for 
patients with advanced prostate cancer with a his-
tory of bone metastases was 1.49 SREs per patient 
year in 15 months in one study [Saad et al. 2002], 
and in patients with RCC and at least one site of 
bone metastases, the mean skeletal morbidity rate 
was 3.38 [Lipton et al. 2003].
Pooled data from two multicenter, randomized, 
placebo-controlled trials of pamidronate in 
patients with metastatic prostate cancer and 
bone pain demonstrated no significant treat-
ment benefit as measured by reduction in SREs 
or palliation of bone pain [Small et al. 2003]. In 
contrast, ZOL, a much more potent NBP than 
pamidronate, has demonstrated broad efficacy 
in the context of SRE prevention in patients 
with bone metastases from multiple tumor types, 
including GU malignancies [Rosen et al. 2004; 
Saad et al. 2004; Saad and Lipton, 2005].
A placebo-controlled, randomized, phase 3 trial 
(N = 643) evaluating the efficacy of ZOL (4 mg 
intravenously over 15 min every 3 weeks) for 
prevention of SREs in patients with bone metas-
tases from CRPC followed 122 patients for 24 
months [Saad et al. 2004]. The incidence of at 
least one SRE was significantly lower among 
patients receiving ZOL (38% versus 49%, p = 
0.028). Treatment with ZOL resulted in a sig-
nificant reduction in the ongoing risk of SREs by 
36% (p = 0.002) and significantly reduced the 
median time to first SRE (488 days versus 321 
days; p = 0.009) [Saad et al. 2004]. The annual 
incidence of SREs was 0.77 for patients in the 
ZOL treatment group compared with 1.47 for 
the placebo group (p = 0.005) [Saad et al. 2004]. 
In an exploratory analysis in 422 patients with 
CRPC, the effect of ZOL (4 mg every 3 weeks) 
on SRE incidence was stratified according to 
baseline pain status [Saad and Eastham, 2010]. 
Among patients with baseline bone pain, ZOL 
reduced the proportion of patients with at least 
one SRE by 18% versus placebo, and by 39% in 
patients without pain at baseline.
A retrospective, subset analysis of patients with 
RCC (n = 74) enrolled in a single multicenter, 
prospective, placebo-controlled trial of ZOL 
for treatment of skeletal metastases from solid 
tumors has been reported at 9-month [Lipton 
et al. 2003] and 21-month follow up [Saad and 
Lipton, 2005]. The trial enrolled patients with a 
variety of solid tumors, including 74 patients 
with RCC [Lipton et al. 2003]. At 9-month fol-
low up, ZOL therapy significantly reduced the 
proportion of patients in this subset with an SRE 
(37% versus 74%; p = 0.015) and reduced the 
risk of developing an SRE by 61% compared 
with placebo [hazard ratio (HR) = 0.394; p = 
0.008] [Lipton et al. 2003]. The extended 
21-month follow up of 46 patients in the RCC 
subset demonstrated continued benefit of ZOL 
Study N Study population Arms Outcome
Fizazi et al. 
[2011]
1904 CRPC with bone 
metastases
Subcutaneous Dmab 120 
mg plus intravenous PBO 
versus intravenous ZOL 
4 mg plus subcutaneous 
PBO both arms every 4 
weeks
Dmab median time to first 
on-study SRE (20.7 versus 17.1 
months; p = 0.008)
Data from Saad et al. [2002, 2004], Saad and Lipton [2005], Lipton et al. [2003], Zaghloul et al. [2010], Small et al. [2003], Ernst et al. [2003], Mason  
et al. [2007], Dearnaley et al. [2003, 2009], Fizazi et al. [2009, 2011], Henry et al. [2011].
BC, breast cancer; BP, bisphosphonate; CLO, clodronate; Dmab, denosumab; CRPC, castration-resistant prostate cancer; HR, hazard ratio;  
MM, multiple myeloma; NTX, N-telopeptide of type I collagen; OS, overall survival; PAM, pamidronate; PBO, placebo; PC, prostate cancer;  
PFS, progression-free survival; RCC, renal cell carcinoma; SMR, skeletal morbidity rate; SRE, skeletal-related event; ZOL, zoledronic acid.
Table 1. (Continued)
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with a significantly delayed time to first SRE by 
nearly 1 year and a significantly delayed time to 
disease progression compared with placebo (586 
days for ZOL versus 89 days for placebo; p = 
0.014) [Saad and Lipton, 2005]. A retrospective 
survival analysis of patients with RCC enrolled 
in this same phase III study demonstrated that 
ZOL therapy was associated with a significant 
improvement in overall survival compared with 
placebo (11.4 versus 7.1 months, respectively; 
HR = 0.54; p = 0.014) [Michaelson et al. 2010].
Additionally, a recent prospective, randomized, 
placebo-controlled trial has also confirmed the 
benefit of ZOL in patients with bladder cancer 
and bone metastases (N = 40) [Zaghloul et al. 
2010]. Patients treated with ZOL experienced a 
significantly reduced number of SREs by 54% 
(p = 0.001), prolonged time to first on-study 
SRE (p = 0.0001), and decreased bone pain scores 
compared with placebo (p = 0.015). Notably, 
there was a significantly increased 1-year survival 
rate for patients in the ZOL treatment group 
(36.3% versus 0% for placebo; p = 0.004). These 
studies demonstrate consistent reduction and 
delay in the development of SREs for patients 
with GU malignancies who are treated with ZOL.
Recently, Dmab achieved noninferiority versus 
ZOL in delaying the time to first on-study SRE 
(20.6 versus 16.3 months, respectively) in patients 
with bone metastases from solid tumors (excluding 
breast and prostate cancer) or multiple myeloma 
(N = 1776; HR = 0.84; 95% confidence interval 
[CI] 0.71–0.98; p = 0.0007) [Henry et al. 2011]. 
It is important to note that the patient population 
in this trial included only 218 (12%) patients with 
GU cancers (n = 155 for RCC; n = 63 for bladder 
cancer) [Henry et al. 2009]. However, post hoc 
analyses by tumor type, although underpowered 
for statistical analyses, demonstrated similar ben-
efits with Dmab for delaying first on-study SRE in 
patients with renal, colorectal, or bladder cancer 
as in the overall trial population [Henry et al. 
2009]. In the overall population, Dmab was nei-
ther statistically superior to ZOL in time to first 
on-study SRE (p = 0.06) nor in time to first and 
subsequent (multiple) SREs (p = 0.14) [Henry et al. 
2011]. Overall survival and disease progression 
were similar for both treatment groups as well. A 
second double-blind, randomized, phase III trial 
compared Dmab and ZOL in 1904 patients with 
CRPC. The median time to first on-study SRE 
was significantly longer in the patients receiving 
Dmab compared with those in the ZOL treatment 
group (20.7 versus 17.1 months, respectively; 
p = 0.008) [Fizazi et al. 2011].
In addition to reduction of SRE risk, antiresorp-
tive agents have been shown to reduce bone pain. 
Patients with CRPC receiving treatment with 
ZOL had a significant reduction in composite 
Brief Pain Inventory (BPI) score compared with 
placebo-treated patients at 2 years (p = 0.024) 
[Saad et al. 2004]. Visual analog scale (VAS) scores 
for pain were significantly reduced in another trial 
of ZOL therapy in patients with solid tumors, 
including prostate cancer (p < 0.05) [Vogel et al. 
2004]. An open-label study of ZOL evaluated the 
safety and efficacy in patients with a variety of 
malignancies, including GU cancers, over the 
course of 12 ZOL (4 mg) infusions administered 
every 3 or 4 weeks. Mean VAS scores decreased 
significantly by 13.9 ± 32.3 (p < 0.0001), and 
mean analgesic scores decreased by 0.56 ± 1.42 
(p < 0.0001) [Kretzschmar et al. 2007]. Recent 
evidence from analysis of phase III data compar-
ing ZOL and Dmab demonstrated similar bene-
fits for both treatments in patients with CRPC 
and bone pain [Patrick et al. 2011]. The propor-
tion of patients with decreased pain interference 
of general activity declined over 18 months, and 
treatment prolonged the time to worsening of pain 
interference for patients in both treatment arms. 
These studies highlight the clinical benefit associ-
ated with prevention of abnormal bone resorption 
in patients with metastatic bone disease. Both 
ZOL and Dmab have been shown to reduce bone 
pain and significantly reduce the incidence of 
SREs in patients with GU malignancies.
Tolerability profiles of antiresorptive agents
Antiresorptive therapies are generally well toler-
ated, particularly with close adherence to estab-
lished guidelines for drug administration and 
adverse event (AE) management. ZOL has a long-
term, well defined safety profile [Saad et al. 2002, 
2004; Aapro and Saad, 2012] with well established 
protocols regarding AE management [Zometa PI, 
2011]. In contrast, because it is a newer antire-
sorptive agent, the long-term safety profile for 
Dmab has yet to be established [Xgeva PI, 2010]. 
However, in the phase III trials of Dmab versus 
ZOL, total AEs and serious AEs were similar 
between treatment arms and both agents were well 
tolerated [Fizazi et al. 2011; Henry et al. 2011].
Osteonecrosis of the jaw (ONJ), renal toxicity, 
hypocalcemia, and acute phase reactions (APRs) 
Therapeutic Advances in Urology 4 (5)
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are AEs of interest that have been reported in 
patients receiving antiresorptive therapies. Rates 
of renal AEs and ONJ were also similar for Dmab 
and ZOL. Indeed, the incidence of ONJ was 
uncommon and was reported at similar rates in 
phase III trials comparing Dmab with ZOL (1–2%) 
in patients with advanced cancer [Fizazi et al. 2011; 
Henry et al. 2011]. AEs potentially associated 
with renal impairment were similar in patients 
with CRPC receiving Dmab (15%) compared with 
ZOL (16%) [Fizazi et al. 2011]. Moreover, renal 
AEs also were similar across treatment arms in 
patients with solid tumors (excluding breast or 
prostate cancer) or multiple myeloma (8% Dmab 
versus 11% ZOL; p = 0.07) [Henry et al. 2011].
Hypocalcemia and APR AEs were notably differ-
ent for Dmab compared with ZOL [Fizazi et al. 
2011; Henry et al. 2011]. Indeed, hypocalcemia 
was significantly more common in patients receiv-
ing Dmab compared with ZOL (11–13% versus 
6%, respectively; p < 0.0001) [Fizazi et al. 2011; 
Henry et al. 2011]. Notably, monitoring serum 
calcium to assess hypocalcemia for patients receiv-
ing Dmab is indicated in the Dmab prescribing 
information [Xgeva PI, 2010]. Furthermore, AEs 
related to APR occurred less frequently in patients 
receiving Dmab (7–8%) compared with ZOL 
(15–18%) [Fizazi et al. 2011; Henry et al. 2011]. 
Generally, APR AEs are easily managed with anal-
gesics, and prophylactic use of acetaminophen 
can reduce the incidence and severity of these 
events [Tanvetyanon and Stiff, 2006; Aapro et al. 
2008]. Furthermore, APRs are generally mild and 
reversible and either do not manifest in subse-
quent cycles of therapy or are of reduced severity 
[Maxwell et al. 2003].
Use of bone turnover markers to 
optimize treatment
The use of bone turnover markers has been sug-
gested as a way to further optimize and define 
treatment outcomes for the antiresorptive agents. 
Given their differing mechanisms of action, there 
may be differences in physiological effect beyond 
prevention of SREs that occurs with ZOL or 
Dmab therapy. Studies suggest that elevated bone 
turnover markers may be associated with a greater 
risk of SREs and reduced survival duration 
[Brown et al. 2005; Cook et al. 2006; Saad et al. 
2007]. For example, a marker of bone metabo-
lism, N-telopeptide of type I collagen (NTX), 
which is a marker of osteoclast-mediated bone 
resorption, has been identified and provides a use-
ful surrogate measure for monitoring skeletal 
health in patients with bone metastases [Coleman 
et al. 2005, 2011]. In an exploratory analysis of 
data from three separate phase III trials of ZOL in 
patients with bone metastases, 61% (193/314) of 
patients with CRPC had elevated NTX levels at 
baseline [Lipton et al. 2008]. Normalization of 
NTX after 3 months of ZOL therapy correlated 
with a 59% reduced risk of death [relative risk 
(RR) = 0.41; 95% CI 0.29–0.59; p < 0.0001] 
(Figure 1), a nonsignificant 29% reduced rate of 
first fracture (p = 0.3653), and a 49% increase in 
SRE-free survival (p = 0.0009) compared with 
E-N (136 at risk, 86 events)
p < 0.0001E-E (57 at risk, 47 events)
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Figure 1. Kaplan–Meier survival estimates stratified by baseline and 3-month N-telopeptide of type I collagen 
(NTX) levels. Patients with bone metastases from hormone-refractory prostate cancer treated with zoledronic 
acid. E-E, patients with elevated baseline and 3-month NTX; E-N, patients with elevated baseline and normalized 
3-month NTX; N, patients with normal baseline NTX. Reprinted with permission from Lipton et al. [2008].
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patients with persistently elevated NTX levels 
[Lipton et al. 2008]. In a study of patients with 
prostate cancer undergoing hormonal therapy it 
was reported that elevated levels of bone turnover 
markers correlate with recurrence and progres-
sion of bone metastases [Noguchi et al. 2003]. 
Thus, bone turnover markers may have utility for 
assessing response to treatment in patients with 
bone metastases, including overall tumor response. 
In fact, in a recent study of patients with prostate 
cancer metastatic to bone undergoing ZOL treat-
ment, overall survival was longer in patients whose 
bone turnover marker levels decreased within 3 
months [Izumi et al. 2012].
Denosumab therapy is also associated with 
reduced NTX levels that correlate with fewer on-
study SREs [Fizazi et al. 2009, 2011]. In the 
phase III trial comparing Dmab with ZOL for 
treatment of bone metastases in CRPC, Dmab 
was associated with significantly greater reduc-
tions in NTX and bone-specific alkaline phos-
phatase compared with ZOL [Fizazi et al. 2011]. 
However, both agents reduced bone turnover 
marker levels, and there was no difference between 
Dmab and ZOL in time to disease progression 
(HR = 1.06, p = 0.30) or overall survival (HR = 
1.03, p = 0.65) [Fizazi et al. 2011]. Survival was 
not analyzed according to bone turnover marker 
response. Another study that evaluated the effect 
of Dmab on BMD and turnover markers in 
postmenopausal women with low bone density 
observed a reversal of effect on BMD and turno-
ver makers such that levels of bone alkaline phos-
phatase and NTX increased above baseline levels 
after discontinuation of Dmab [Miller et al. 2008]. 
Further research regarding the correlation of 
bone turnover marker levels with anticancer and 
bone disease outcomes from antiresorptive thera-
pies will aid in understanding differences between 
the current antiresorptive agents.
Evidence for the potential anticancer 
benefits of antiresorptive agents
In preclinical and clinical studies in patients 
with advanced cancer, BPs have been shown to 
elicit a variety of anticancer responses from 
direct effects on tumor cell survival and prolif-
eration to indirect antitumor effects mediated by 
their modulation of angiogenesis, host immuno-
surveillance, and inhibition of tumor-promoting 
processes in the bone microenvironment [Yuasa 
et al. 2007; Clezardin, 2011]. In general, antire-
sorptive agents inhibit a broad range of cellular 
functions, including cell differentiation, which is 
particularly relevant in the context of osteoclast 
activity and may provide important anticancer 
effects as well. For example, the NBP-mediated 
inhibition of farnesyl pyrophosphate synthase 
also causes accumulation of isopentenyl-pyroph-
osphate (IPP) that has been shown to activate γδ 
T cells. The γδ T cells are a subset of the periph-
eral blood T cells that play a role in tumor-specific 
immunity. Cytotoxic activity of γδ T cells toward 
a range of malignant cell types, including blad-
der cancer, has been demonstrated in vitro [Kato 
et al. 2001].
Zoledronic acid is a potent inducer of γδ T-cell 
proliferation, which may in part account for ZOL-
induced anticancer effects [Mariani et al. 2005]. 
Two small studies in patients with prostate cancer 
have shown that ZOL activates and increases the 
number of γδ T cells [Dieli et al. 2007; Naoe et al. 
2010], and in one of the studies ZOL treatment 
was associated with a reduction in prostate-spe-
cific antigen (PSA) velocity in 50% (5/10) of the 
patients [Naoe et al. 2010]. Interestingly, activa-
tion of γδ T cells after ZOL treatment alone was 
also associated with reduced PSA velocity in two 
patients [Naoe et al. 2010]. These studies further 
suggest that ZOL combined with interleukin-2 
may offer further benefit in terms of γδ T-cell pro-
liferation and immunotherapy effect.
In addition to immunomodulatory effects, data 
suggest that NBPs may inhibit tumor-mediated 
angiogenesis and render the bone microenviron-
ment less conducive to growth of micrometastases 
[Wood et al. 2002]. The effect of NBPs on angio-
genesis and neovascularization is presumed to be 
related to inhibition of angiogenic factors [eg, vas-
cular endothelial growth factor, platelet-derived 
growth factor, basic fibroblast growth factor 
(bFGF)] necessary for proliferation of endothelial 
cells [Wood et al. 2002]. Furthermore, ZOL has 
been shown to modulate cellular adhesion and 
migration and inhibit angiogenesis induced by 
subcutaneous implants containing bFGF in vivo 
[Wood et al. 2002]. The effects of NBPs on the 
bone microenvironment, angiogenesis, and stimu-
lation of immune surveillance via γδ T-cell prolif-
eration suggest the potential of these agents for 
additional anticancer benefits.
In addition to indirect effects, preclinical studies 
have shown direct anticancer activity of ZOL in 
RCC cell lines. Indeed, ZOL treatment induced 
apoptosis in several RCC cell lines [Pandha et al. 
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2006; Ullen et al. 2009; Zwolak et al. 2010]. 
Furthermore, a single case study in which lung 
and bone metastases displayed remission after BP 
therapy and a small retrospective analysis demon-
strating improved objective response rate with 
ZOL therapy add support for the potential direct 
anticancer effects of ZOL in RCC [Kijima et al. 
2008, 2009].
The potential anticancer activity of ZOL has also 
been observed when used in combination with 
traditional anticancer agents. A number of studies 
have demonstrated an additive or synergistic effect 
of ZOL with chemotherapy against leukemias and 
solid tumors [Kimura et al. 2004; Matsumoto 
et al. 2005; Neville-Webbe et al. 2005, 2006, 
Sato et al. 2006]. The combination of an NBP 
(minodronic acid) with cisplatin or paclitaxel has 
been shown to kill bladder cancer cells in culture 
and has inhibited growth of bone metastases in 
vivo in a bladder cancer mouse model [Sato et al. 
2006]. Doxorubicin-induced apoptosis has also 
been shown to be synergistically enhanced by the 
use of ZOL in breast and prostate cancer cells 
[Neville-Webbe et al. 2005]. This study highlights 
the importance of drug sequence when adding 
ZOL for treatment of malignant cells, as apopto-
sis was only enhanced by the use of ZOL after 
treatment by doxorubicin. There is also evidence 
for an additive anticancer effect of ZOL when 
combined with endocrine therapy. Long-term 
follow up of a trial comparing adjuvant endocrine 
therapy with or without ZOL has recently dem-
onstrated that the addition of ZOL improved 
disease-free survival of patients with early-stage 
breast cancer (92% versus 88%, log-rank p = 0.008) 
[Gnant et al. 2011].
Circulating tumor cells (CTCs) have not been 
extensively explored in GU malignancies; how-
ever, data from other solid tumors suggest that 
CTCs are associated with a worse prognosis and 
that reducing CTC numbers may be associated 
with reduced risk of recurrent/progressive disease 
[Cristofanilli et al. 2004, 2005; Budd et al. 2006; 
Hayes et al. 2006; Janni et al. 2011]. Two studies 
in metastatic prostate cancer have demonstrated a 
correlation between greater numbers of CTCs, 
elevated serum PSA, and poor overall survival 
(Figure 2) [Moreno et al. 2005; Garcia et al. 
2007]. Another study evaluating CTCs in relation 
to disease spread and outcome in patients with 
CRPC found that the baseline CTC number was 
strongly correlated with survival, and that the pre-
dictive value increased when baseline PSA and 
serum albumin were included in the analysis. 
Higher numbers of CTCs were observed in 
patients with bone metastases compared with 
other sites of metastases [Danila et al. 2007]. 
Most recently, research in patients with meta-
static CRPC receiving chemotherapy showed 
that CTCs and lactate dehydrogenase levels may 
be useful as surrogate markers for overall survival 
[Scher et al. 2011]. ZOL has previously been 
shown to reduce CTC numbers in patients with 
cancer, suggesting another mechanism by which 
ZOL may potentially improve overall outcomes 
in patients with GU malignancies [Solomayer 
et al. 2012; Aft et al. 2010]. These observations of 
a potential direct anticancer effect from ZOL 
have not been reported with Dmab, indicating 
important differences in the pharmacologic 
effects of these agents that are likely based on 
their different mechanisms of action and phar-
macokinetic profiles.
To date, there is no clinical evidence of antican-
cer effects with Dmab; however, preclinical stud-
ies with inhibitors of RANKL signaling (which 
may mimic Dmab effects) have been conducted. 
Potential mechanisms of anticancer effects from 
Dmab are related to the role of RANK, RANKL, 
and endogenous osteoprotegerin (OPG), a sur-
rogate for Dmab activity in animal studies, in 
regulation of osteoclastogenesis and bone resorp-
tion [Wada et al. 2006]. While it has been 
shown that OPG binding to RANKL prevents 
the osteolytic action of prostate cancer [Zhang 
et al. 2001], OPG can prevent tumor necrosis 
factor-related apoptosis-induced ligand (TRAIL)-
mediated apoptosis [Holen et al. 2002]. In con-
trast, the soluble receptor activator of nuclear 
factor κB (sRANK) inhibited RANKL in a mouse 
model but did not prevent TRAIL-induced apop-
tosis and did reduce prostate tumor cell growth 
[Zhang et al. 2003]. These data suggest that inhi-
bition of RANKL by molecules that do not inter-
act with TRAIL may prevent metastatic cancer 
progression in bone. However, a preclinical study 
showed that Dmab could not induce apoptosis 
or inhibit proliferation of a breast cancer cell 
line (MCF-7), but that ZOL could [Ebert et al. 
2011]. Moreover, based on the mechanism of 
Dmab’s antiresorptive effect, an immune- 
mediated anticancer response to Dmab therapy 
is unlikely, and there have been concerns regard-
ing increased immunosuppression resulting 
from RANKL inhibition because, in addition to 
expression on osteoclasts, RANKL is expressed 
on T and B cells of the immune system [Kawai 
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et al. 2006; Benzaïd et al. 2011]. Indeed, a pre-
clinical study has shown that Dmab does not 
induce γδ T-cell expansion in a breast cancer 
model [Benzaïd et al. 2011].
Although there is no clinical evidence for antitu-
mor activity associated with Dmab, a clinical trial 
to assess the potential of Dmab to prevent bone 
metastases in patients with prostate cancer and at 
high risk for development of bone metastases has 
recently been presented [Oudard et al. 2011; 
Smith et al. 2012]. In this phase III trial in patients 
with CRPC at high risk for bone metastases (N = 
1432), Dmab (120 mg every 4 weeks) signifi-
cantly prolonged bone-metastases-free survival 
by 4.3 months versus placebo (29.5 versus 25.2 
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months, respectively; HR = 0.85, p = 0.028) 
[Oudard et al. 2011; Smith et al. 2012]. However, 
Dmab did not prolong progression-free (HR = 
0.89, p = 0.093) or overall survival (HR = 1.01, 
p = 0.91) versus placebo [Oudard et al. 2011; 
Smith et al. 2012].
Conclusions
Questions remain regarding the optimal duration 
and dosing of antiresorptive therapies to prevent 
or palliate SREs. Bone turnover markers such as 
NTX may be useful surrogates to monitor thera-
peutic effects on bone and help guide future trials. 
Furthermore, assessment of circulating angio-
genic markers and CTCs may provide greater 
insight into the anticancer activity of antiresorp-
tive therapies. Currently, three large trials are 
ongoing in patients with prostate cancer to evalu-
ate the effect of ZOL on event-free and overall 
survival [Coleman et al. 2011].
Clinical trials of antiresorptive agents confirm the 
value of this therapy in prevention of potentially 
debilitating and life-limiting SREs, and provide 
evidence for a further role in delaying disease 
progression and prolonging survival in some cases. 
The potential for synergistic benefit with com-
bined chemotherapy or androgen therapy plus 
ZOL in GU malignancies is encouraging, and 
future trials are anticipated.
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